We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Delivers Candidate Drug in GSK Alliance
News

Galapagos Delivers Candidate Drug in GSK Alliance

Galapagos Delivers Candidate Drug in GSK Alliance
News

Galapagos Delivers Candidate Drug in GSK Alliance

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Delivers Candidate Drug in GSK Alliance"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos will now start scale-up chemistry and comprehensive safety evaluation to initiate Phase I clinical trials in early 2012.

This latest pre-clinical candidate is a small molecule that meets the chemical and biological criteria set by GSK for a potential new medicine. Galapagos will now start scale-up chemistry and comprehensive safety evaluation, with the aim to initiate Phase I clinical trials in early 2012.

"The arthritis alliance with GSK has been very fruitful in delivering promising candidate drugs," said Onno van de Stolpe, CEO of Galapagos. "In this alliance, we currently have two clinical trials, with plans to progress this new candidate into the clinic next year."

Advertisement